Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Blonanserin

An atypical antipsychotic acting on dopamine (D2/D3) and serotonin (5-HT2A) receptors, developed in Japan and launched in 2008 for the treatment of schizophrenia. This family brings together the active ingredient, metabolites, labelled standards and other impurities.

Did you know?In 2019 Japan approved a skin-patch version: it was the world's first transdermal formulation of an antipsychotic.

BlonanserinGo to the active ingredient →
BlonanserinActive ingredientBlonanserinCat. No. P-B094-001CAS 132810-10-7
Blonanserin-d5Isotopically labelledBlonanserin-d5Cat. No. P-B094-004CAS 1346599-86-7

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.